Aglaia is founded on the principle that the willingness to take risks on the very early stage ventures of today results in opportunities that may grow into the winning companies of tomorrow. As such, we are typically the first provider of capital for startup and early stage companies and a driving force behind product development.
Since the number of technological discoveries in the biomedical field is growing fast, specialized knowledge regarding the translation of these discoveries into novel products is a prerequisite for success. Aglaia’s focus on oncology is considered to be a differentiating asset. We invest in novel tools and technologies as well as components of contemporary drug development.
Opportunities may be derived from research centers as well as from corporate spinouts. We select, develop and commercialize promising technologies up to a level where the technology becomes attractive to larger investors or pharmaceutical and biotech companies.
Technologies meeting the following criteria are eligible for further evaluation:
We do not ask scientists and entrepreneurs to cover all these topics in detail. We merely seek to discuss these criteria and work together in defining a sound business scenario.
ISA Pharmaceuticals and Regeneron Announce Strategic Immuno-Oncology Collaboration
Cristal Therapeutics awarded €2.5 million Horizon 2020 grant to advance its CriPec®-docetaxel through Phase 2 trials